Salubris Pharma's SAL0140 receives clinical trial approval

Shenzhen Salubris Pharmaceuticals (SZSE:002294) announced that it has received approval from the National Medical Products Administration to conduct clinical trials for its novel small molecule drug, SAL0140, indicated for the treatment of uncontrolled hypertension. SAL0140 is a proprietary aldosterone synthase inhibitor with potential to address unmet clinical needs in patients with hypertension, including those with refractory hypertension. Preclinical studies have demonstrated SAL0140's selective inhibition of aldosterone synthase and its ability to effectively control blood pressure in hypertensive models. While this development enriches Salubris Pharma’s pipeline of innovative products, the company cautions that drug development involves considerable risk, and the impact on near-term financial performance is uncertain. The company will disclose further updates regarding the clinical trial progress in compliance with regulatory requirements.